Holen Sie sich die Stockscreener-App
12.23
0.20%
0.025
Kalvista Pharmaceuticals Inc Aktie (KALV) Neueste Nachrichten
Is KalVista Pharmaceuticals Inc. (4XC1) stock included in top ETFsMarket Growth Summary & Breakout Confirmation Alerts - newser.com
Is KalVista Pharmaceuticals Inc. forming a bottoming base2025 Trading Recap & Real-Time Chart Pattern Alerts - newser.com
What drives KalVista Pharmaceuticals Inc 4XC1 stock priceEarnings Per Share Trends & Affordable Trading Strategies - earlytimes.in
Can KalVista Pharmaceuticals Inc. stock sustain free cash flow growthJuly 2025 Highlights & Weekly Breakout Opportunity Watchlist - newser.com
KalVista Pharmaceuticals Completes Convertible Notes Sale - TipRanks
Custom strategy builders for tracking KalVista Pharmaceuticals Inc.2025 Dividend Review & Breakout Confirmation Trade Signals - newser.com
Published on: 2025-09-28 22:29:02 - earlytimes.in
With HAE Drug EKTERLY Off To A Strong Start, Is Now The Time To Keep An Eye On KalVista Stock? - Nasdaq
KalVista prices upsized offering of $125M of 3.250% notes due 2031 - MSN
KalVista to offer $110M in convertible notes; shares down 10% - MSN
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy Congress - Business Wire
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Down 6.9%What's Next? - MarketBeat
Ekterly approved as on-demand therapy for HAE in EU, Switzerland - Angioedema News
KalVista Prices Upsized Offering of $125.0 Million of 3.250 Convertible Senior Notes Due 2031 - MarketScreener
KalVista Pharma falls after $125 mln convertible debt sale - TradingView
KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031 - Business Wire
KalVista Pharmaceuticals Prices $125 Million Notes Offering - MarketScreener
KalVista plans to offer $110 million in convertible notes By Investing.com - Investing.com Canada
KalVista prices $125 million convertible senior notes offering - Investing.com
KalVista prices $125 million convertible senior notes offering By Investing.com - Investing.com Nigeria
Kalvista Pharmaceuticals stock falls after convertible notes offering By Investing.com - Investing.com Canada
Kalvista Pharmaceuticals announces proposed offering of $110.0 million of convertible senior notes - MarketScreener
KalVista plans to offer $110 million in convertible notes - Investing.com
Kalvista Pharmaceuticals stock falls after convertible notes offering - Investing.com India
KalVista (KALV) Plans $110M Convertible Senior Notes Offering - GuruFocus
KalVista Pharmaceuticals Proposes Private Offering of $110 Million of Convertible Notes; Shares Fall After Hours - MarketScreener
KalVista Pharma falls after announcing $110 mln convertible debt offering - TradingView
KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes - The Joplin Globe
KalVista Pharmaceuticals Experiences Evaluation Revision Amidst Mixed Market Signals - Markets Mojo
Hereditary Angioedema Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight - Barchart.com
KalVista Pharmaceuticals, Inc. $KALV Shares Purchased by Rhumbline Advisers - Defense World
Hereditary Angioedema Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight - openPR.com
KalVista’s Regulatory Victory Meets Market Skepticism - AD HOC NEWS
KalVista’s Ekterly approved in EU and Switzerland - The Pharma Letter
KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema - BioSpace
Decliners Report: What analysts say about KalVista Pharmaceuticals Inc stockJuly 2025 Macro Moves & Scalable Portfolio Growth Methods - خودرو بانک
KalVista, Ionis/Sobi among latest to win EU nod for rare disease drugs - MSN
Analyzing KalVista Pharmaceuticals Inc. with risk reward ratio charts2025 Investor Takeaways & Daily Price Action Insights - newser.com
Hereditary Angioedema Pipeline Drugs Report 2025 - openPR.com
KalVista Pharmaceuticals’ Hereditary Angioedema Drug Approved In EU, Switzerland: Retail Sees Stock Rallying To $22 In A Year - Stocktwits
KalVista’s oral HAE treatment Ekterly receives EU and Swiss approval - Investing.com India
Earnings Miss: Can KalVista Pharmaceuticals Inc. deliver consistent dividendsJuly 2025 Market Mood & Low Risk Profit Maximizing Plans - khodrobank.com
KalVista (KALV) Secures EU Approval for Hereditary Angioedema Tr - GuruFocus
KalVista’s oral HAE treatment Ekterly receives EU and Swiss approval By Investing.com - Investing.com Nigeria
Gold miners, Perpetua Resources, KalVista Pharmaceuticals - TradingView
KalVista (KALV) Gains European and Swiss Approval for Ekterly - GuruFocus
KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY - Business Wire
2.36%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):